Wrap Text
ASPI to participate in Canaccord Genuity’s 46th annual growth conference on August 12, 2026
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI TO PARTICIPATE IN CANACCORD GENUITY'S 46TH ANNUAL GROWTH CONFERENCE ON AUGUST 12, 2026
DALLAS, July 30, 2026 -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"), an
advanced materials company focused on developing technologies and processes for the production of
critical materials used in multiple industries, today announced that Viktor Petkov, Chief Commercial Officer,
will deliver a company presentation on Wednesday, August 12, 2026, at 8:00 a.m. ET.
A live audio webcast of the presentation will be available in the Investors section of the Company's website
at www.aspisotopes.com. A replay will be available on the Company's website within 48 hours after the
event.
About ASP Isotopes Inc.
ASP Isotopes is developing a differentiated isotope enrichment platform to strengthen global supply chain
access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy.
The Company's proprietary technologies, the Aerodynamic Separation Process ("ASP technology") and
Quantum Enrichment ("QE technology"), are designed to enable the production of isotopes for a range of
industrial and advanced technology applications. ASP Isotopes operates isotope enrichment facilities in
Pretoria, South Africa, focused on the enrichment of low atomic mass elements, or light isotopes. For more
information, please visit www.aspisotopes.com.
Important Additional Information and Where to Find It
In connection with the proposed merger and related transactions (the "Proposed Transactions") involving
ENDRA Life Sciences Inc. ("ENDRA"), ASP Isotopes, Renergen, a subsidiary of ASP Isotopes
("Renergen"), and Noble Africa, a subsidiary of ASP Isotopes and holding company for Renergen ("Noble
Africa"), ENDRA intends to file relevant materials with the U.S. Securities and Exchange Commission (the
"SEC"), including a registration statement on Form S-4 (the "Form S-4") that will contain a proxy statement
(the "Proxy Statement") and prospectus. This communication is not a substitute for the Form S-4, the Proxy
Statement or for any other document that ENDRA may file with the SEC and/or send to its stockholders in
connection with the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE
URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT
DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENDRA,
ASP ISOTOPES, RENERGEN, NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND RELATED
MATTERS. Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy
Statement and other documents filed by ENDRA and ASP Isotopes with the SEC (when they become
available) through the website maintained by the SEC at www.sec.gov. ENDRA's Internet website address
is www.endrainc.com. ENDRA's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, including exhibits, and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page
of its Internet website as soon as reasonably practicable after it electronically files such material with, or
furnishes such material to, the SEC.
Participants in the Solicitation
ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and certain
of their executive officers and other members of management may be deemed to be participants in the
solicitation of proxies from ENDRA's stockholders in connection with the Proposed Transactions under the
rules of the SEC. Information about ENDRA's directors and executive officers, including a description of
their interests in ENDRA, is included in ENDRA's most recent Annual Report on Form 10-K for the year
ended December 31, 2025. Information about ASP Isotopes' directors and executive officers, including a
description of their interests in ASP Isotopes, is included in ASP Isotopes' most recent Annual Report on
Form 10-K for the year ended December 31, 2025. Additional information regarding the persons who may
be deemed participants in the proxy solicitations, including the directors and executive officers of Renergen,
and a description of their direct and indirect interests, by security holdings or otherwise, will also be included
in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they
become available. These documents can be obtained free of charge from the sources indicated above.
No Offer or Solicitation
This press release is not intended to and does not constitute a solicitation of a proxy, consent or approval
with respect to any securities or in respect of the Proposed Transactions or an offer to sell or the solicitation
of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to
the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in
any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means
of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and
otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to
be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made
directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such
jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile
transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national
securities exchange, of any such jurisdiction.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs,
expectations, and assumptions regarding the future of the Company's business, future plans and strategies,
projections, anticipated events and trends, the economy, and other future conditions. Forward-looking
statements can be identified by words such as "anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "might," "plans," "projects," "will," and words of a similar nature. Examples of forward-
looking statements include, but are not limited to, statements regarding the Company's business strategy
and market opportunity, and expectations regarding the structure, timing and completion of the Proposed
Transactions. Because forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside of
the Company's control. Actual results, financial condition, and events may differ materially from those
indicated in the forward-looking statements based upon a number of factors. Forward-looking statements
are not a guarantee of future performance or developments. You are strongly cautioned that reliance on
any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you
should not rely on any of these forward-looking statements.
There are many important factors that could cause actual results and financial condition to differ materially
from those indicated in the forward-looking statements, including, but not limited to: the outcomes of various
strategies and projects undertaken by the Company; the potential impact of laws or government regulations
or policies in South Africa, the United Kingdom or elsewhere; the Company's future capital requirements
and sources and uses of cash; the Company's ability to obtain funding for its operations and future growth;
the Company's reliance on the efforts of third parties; the Company's ability to complete the construction
and commissioning of its enrichment plants or to commercialize isotopes using the ASP technology or the
Quantum Enrichment Process; the Company's ability to obtain regulatory approvals for the production and
distribution of isotopes; the financial terms of any current and future commercial arrangements; the
Company's ability to complete certain transactions and realize anticipated benefits from acquisitions and
contracts; dependence on the Company's Intellectual Property (IP) rights, certain IP rights of third parties;
the competitive nature of the Company's industry; the risk that the conditions to the closing or
consummation of the Proposed Transactions are not satisfied, including the failure to timely obtain approval
of the Proposed Transactions from ENDRA stockholders, if at all; uncertainties as to the timing of the
consummation of the Proposed Transactions and the ability of each of ENDRA and Noble Africa to
consummate the Proposed Transactions; and the other risks and uncertainties disclosed in Part I, Item 1A.
"Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025
(as amended) and in the Company's subsequent reports filed with the SEC.
Any forward-looking statement made by the Company in this press release is based only on information
currently available to the Company and speaks only as of the date on which it is made. The Company
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new
information, future developments or otherwise. No information in this press release should be interpreted
as an indication of future success, revenues, results of operations, or stock price. All forward-looking
statements herein are qualified by reference to the cautionary statements set forth herein and should not
be relied upon.
Contact
IR@ASPIsotopes.com
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the JSE.
30 July 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 30-07-2026 02:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
